physical activity (n=12) or medication (n=10) changes, or making a HCP appointment (n=12). High score on a Diabetes Knowledge Test was a statistically significant predictor of taking action (odds ratio: 2.07). However, neither taking action nor increased SMBG frequency were associated with improved glycaemic control. Conclusions: Responding to SMBG test results and increased testing frequency were not associated with improved glycaemic control in the short-term. There is a lack of knowledge surrounding SMBG in non-insulin treated patients.
INTRODUCTION
The value of self-monitoring of blood glucose (SMBG) in insulin-treated patients with diabetes mellitus is well established 1, 2 , but its utility in non-insulin treated patients remains controversial. Despite this, SMBG is becoming increasingly common 3 (and costly 4 ) among this group of patients. Proponents of SMBG argue that it can provide 'real time' information about hyperglycemic or hypoglycemic excursions, and thus help patients make day-to-day behavioural choices to help keep blood glucose levels within clinically recommended target ranges 5 . However, there is limited empirical evidence of clinical benefit. A recent report from an NHS Diabetes Working Group, that included a systematic review of 26 RCTs and 36 observational studies, concluded that SMBG is associated with only minimal improvements in glycaemic control, and is unlikely to be effective in non-insulin treated patients 6 . SMBG is no longer routinely recommended to patients who do not use insulin 6, 7 .
What is almost universally lacking from studies on monitoring is consideration of how (and why) patients use self-monitoring as a self-management tool. Whether an appropriate response, or indeed any response at all, is made to high or low blood glucose readings is the key to understanding whether self-monitoring can be clinically effective 8 .
Many insulin-using patients adjust insulin doses in response to readings, but non-insulin using patients cannot do this. In a large recent survey in the United States, 56% of patients took no action at all in response to out-of-range SMBG readings 3 . Such patients are unlikely to derive clinical benefit from SMBG. Heller et al (2010) have identified a lack of education among patients in how to interpret and use data from SMBG 6 .
However, we raise the question as to whether there may be some groups of patients with type 2 diabetes mellitus who monitor regularly, have received suitable education and make appropriate responses to high and low readings, for whom a clinical benefit might be identifiable. In this cross-sectional study in Tayside, Scotland, we therefore administered questionnaires to patients with type 2 diabetes mellitus who had no record of insulin use to investigate their SMBG behaviours in detail. We then linked the information obtained to clinical data from a population-based diabetes clinical information system. We were thus able to evaluate the associations between SMBG behaviour (and other clinical and demographic variables) and glycaemic control.
MATERIALS AND METHODS
This study was carried out in the population of Tayside, Scotland, UK (approx. 400,000 people Primary data collected by questionnaire were record-linked to patients' clinical information on the SCI-DC clinical information system, then anonymised prior to analysis. Data were also assembled for patients who were not interviewed.
Every patient was assigned an index date. This was either the date that they were interviewed, or if they were not interviewed, the date that the first patient in their practice was interviewed. To derive an objective measure of SMBG frequency, the number of reagent strips that had been dispensed in the 12 month period prior to the index date was calculated for every eligible patient in the study. This number was derived from total numbers of packs dispensed recorded on the prescription form. The most recent HbA1c value in the 6 month period prior to the index date of every study patient was also identified from SCI-DC. This study had ethical approval from the Tayside Committee for Medical Research Ethics (reference 09/S1401/48). The data of those patients who opted-out of being interviewed were analysed anonymously.
RESULTS
There were 629 eligible patients in 23 GP practices, of which GPs withheld permission to approach 61. Among the remaining patients, 111 patients actively opted-out and 225 declined at a later stage or could not be contacted. 232 interviews were therefore completed, of which 207 were analysed (25 patients who had already been advised by their GPs to discontinue monitoring were excluded). The characteristics of the 207 interviewed patients were compared with those of non-interviewed patients and were generally similar, with just over half the interviewed sample male (58%), with a mean age of 63 years (range 36-76 years), and mean diabetes duration of 97 months, compared to 56%, 60 years and 89 months respectively (Table 1) . Nearly one third of interviewed patients had had diabetes mellitus for more than 10 years, with few (8%) diagnosed within the last two years. The mean number of strips dispensed in a 12 month period for patients who received at least some strips was 268 for the 207 interviewed patients and 232 for non-interviewed patients, with respective medians of 200 and 150. Mean HbA1c was 7.45% and 7.77% respectively; this difference was statistically significant. 206 of the 207 interviewed patients reported having experienced a high blood glucose reading, in contrast to only 109 who had experienced a low blood glucose reading.
Among the latter, almost all reported that they had made a dietary change in response (e.g. consuming a biscuit or sugary drink). The 206 patients were subsequently categorised according to how they responded to high blood glucose readings:
No Action: 80 (38.8%) patients reported either taking no action (n=59) or simply checking their blood glucose levels again later (n=21). The reason given for this by 49 (61.3%) patients was that they did not know what action to take. Among the remaining patients, 22 patients were either not concerned / just accepted high readings, eight found that taking action made no difference and one patient found it too difficult.
Some Action: 126 (61.2%) patients took some form of action. These (not mutually exclusive) actions included making changes to diet -predominately cutting down on fats and sugary foods for a few days -(n = 101), increasing physical activity (n = 12), making changes to medication (n = 10), or making an appointment with a health care practitioner (n = 12).
In a univariate regression analysis, females were more likely to report taking action than males, although this was not statistically significant in the multivariate analysis.
However, the most important independent predictor of action appeared to be diabetes knowledge. Patients who scored highly in a Diabetes Knowledge Test were twice as likely to take action as those who scored less well.
We investigated predictors of poor control in the 207 patients who were interviewed (Table 3 ) and again in the entire sample of 629 patients (Table 4) . Among patients for whom HbA1c was available, 28.0% of interviewed patients had HbA1c ≥ 8; the figure was 32.6% in the entire sample. Table 3 shows that older patients were less likely to have poor control, but patients treated with sulphonylureas and metformin in combination, or with injections of exenatide or liraglutide, were more likely to have poor control than patients treated with metformin only. However, SMBG frequency, whether measured by the number of reagent strips dispensed or by self-report, was not associated with glycaemic control; neither was there any discernible associaton between glycaemic control and diabetes knowledge, education or whether a patient took action in response to high results.
In the larger sample, the statistically significant associations with poor glycaemic control, for increasing age, treatment with sulphonylureas and metformin in combination, and with injections, were confirmed (Table 4) . Daily SMBG (measured by strips dispensed)
was associated with poor control in the univariate analysis, but this was no longer evident in the multivariate model.
DISCUSSION
This study shows that SMBG frequency among patients with type 2 diabetes mellitus in Scotland who are not treated with insulin is relatively high, with the mean number of reagent strips dispensed sufficient for monitoring most days. The study also suggests that there is a lack of knowledge surrounding SMBG among non insulin-treated patients, with more than one-third of a sample of 207 of such patients reporting taking no action in response to SMBG results. Over one half of those who reported taking no action stated that this was because they did not know what (or how) to do. However, a minority of these patients did state that they checked their blood glucose levels later if they had a high blood glucose reading. Although this might be considered an appropriate response, these patients were categorized as taking no action for subsequent analyses.
In a regression model, there was an association between an objective measure of diabetes knowledge and whether a patient reported taking action. Patients who scored highly on knowledge were twice as likely to take action as those who scored less well. Although we cannot discount the possibility of social desirability bias (the tendency of respondents to distort the self-reporting of behaviour in a favourable direction, with more knowledgeable patients aware that reporting taking action in response to test results supports the expectations of health care professionals 16 ), the consistent strands of evidence do suggest that a lack of knowledge is a key factor in whether a patient responds to test results. This lack of knowledge may relate to the implications of high readings, the most effective way to reduce SMBG readings or how to make the required behavioural changes; and may be because patients do not receive adequate education surrounding SMBG.
In regression analyses, we also evaluated possible predictors of poor glycaemic control.
Older patients were less likely to have poor glycaemic control in both analyses, and this has been reported in other studies 17, 18 . We also identified treatment with a combination of metformin and sulphonylureas, and treatment with injections of liraglutide and exenatide, as being associated with poor glycaemic control. This is likely to be due to patients with poor glycaemic control being channeled into more aggressive treatment.
In terms of SMBG behavior, patients who reported taking action in response to test results were no less likely to have poor glycaemic control than those who did not make any response. There are several possible explanations for this lack of association. First, it may be that patients who report taking action do not actually take action (as discussed above). Second, it may be that the actions that patients take are ineffective. The most common 'action' was making short term changes to diet, but such reactive behavior may well have no discernible effect on long-term control. Third, we asked patients whether they took action in response to a 'reading that has caused you concern'. However, we did not specifically ask patients how high their readings needed to be before they were 'concerned', so it is difficult to determine whether they took action at the appropriate time or at an appropriate blood glucose level. However, regardless of the explanation, actions that patients are taking -at whatever time -are not associated with improved glycaemic control in the short-term. These results contrast to those of from a recent trial where non-insulin-using patients who adhered to a structured SMBG protocol did have improved glycaemic control 19 . However, this was a relatively intensive intervention whereby patients and clinicians collaboratively evaluated patterns of SMBG results over a 3-day period to plan lifestyle and medication changes; very different to observed practice in our study.
Although there was no association between self-reported SMBG frequency and glycaemic control, daily monitoring as measured objectively by numbers of reagent strips dispensed, was associated with poor control. While this could be a reflection of patients with poor control motivated to monitor more frequently, the association was no longer evident after adjusting for treatment. It is important to recognize the potential confounding effect of treatment in any future cross-sectional, observational studies in this area.
We found no associations between deprivation (in either analysis) and self-reported education level and poor glycaemic control, in contrast to other studies 17, 18 . This is perhaps surprising given the well-established associations between disadvantage and poor outcomes in diabetes 20 . However, it may be that the measures that we used were not sensitive enough to discriminate sufficiently between patients, therefore diluting any effects that were present.
The study was carried out with a self-selected sample of patients who agreed to be interviewed. We did not specifically ask why some patients did not wish to be interviewed, but the demographic characteristics of the interviewed patients were similar to those of the total population. Despite this, we cannot exclude the possibility that their SMBG behaviour was different. The mean number of strips dispensed to them was indeed slightly higher. They also had lower HbA1c, and could perhaps have been more motivated, interested in and positive about SMBG. If this is the case, however, then the lack of knowledge identified among these possibly more motivated patients is even more concerning. Also, it is noteworthy that other associations that were identified in the smaller self-selected group for glycaemic control were confirmed in the entire sample of non-selected patients.
Data for the study came from self-report measures and from electronic records of clinical data from SCI-DC. All patients were interviewed by the same Research Fellow who adhered to a pre-defined protocol for administering the questionnaires. While these questionnaires were either existing, validated measures, or ones that had been developed and tested with a lay service user with diabetes mellitus and then refined in a pilot study, we can not be completely certain that patients gave accurate responses to questions asked.
Further studies conducted on a larger scale may therefore benefit from a more in-depth assessment of content validity to ensure items are collecting responses as intended. In contrast, SCI-DC is a validated population-based clinical information system that has been widely used in epidemiological research, and we are confident in data derived from it. However, in terms of reagent strips dispensed for SMBG, while we know that patients were dispensed the strips, we cannot be sure that they actually used them. They may also have received strips from other sources. We also identified 43 interviewed patients who had received no reagent strips in the 12 month period prior to their index date; although receiving strips in 2009 was an eligibility criterion, as was self-reported current monitoring. It is possible that they had stocks of reagent strips dispensed previously, and/or they were monitoring very infrequently, and indeed a similar number self-reported infrequent monitoring. In general though, the numbers of strips dispensed were higher than those reported in earlier studies in Tayside 21 , suggesting that most of the interviewed patients received enough strips to monitor at least 3-4 times per week, and tallying fairly well with self-report frequency.
This was a cross-sectional study in that all the data were collected from interviewed patients at the same point in time. This can mean that it is difficult to determine the order in which particular events or outcomes occurred. However, HbA1c values were electronically recorded and we identified the HbA1c measure nearest in time over a 6-month period prior to the date of the patient's interview. This was in order to relate the HbA1c measure in time to the SMBG practices that patients were describing.
We believe that the associations we identified in this study are valid. However, the number of interviewed patients was relatively small, so it is possible that the study was not sufficiently powered to detect some associations which were relatively large. For example, with a sample size of 207, divided equally between two groups, the study had 80% power to detect differences in categorical variables of around 14%. A larger sample would be needed to detect smaller differences. Despite this limitation, we have gone further than other studies in attempting to characterize how patients monitor and respond to test results. Despite this, the study still gives a strong indication that SMBG, as currently practised in Tayside, is not associated with improved glycaemic control in the short-term, and highlights the lack of knowledge surrounding SMBG in non-insulin treated patients with type 2 diabetes mellitus. It is also important to establish whether these results would be replicated in other regions and countries.
The American Association of Diabetes Educators has recently made a call for all patients with diabetes to receive standardised and tailored education on SMBG, advocating that 'safe and appropriate blood glucose monitoring methods need to be taught including selfmanagement skills that incorporate and utilize the data obtained from blood glucose monitoring for an individualized program of self care' 22 . This should not only include education on the mechanics of operating meters, how often to test, and how to record the results, but also what to do with blood glucose results, target blood glucose goals, and when to test. Similarly, one of the key recommendations from NHS Diabetes (2010) 6 is that 'SMBG should only be used within a care package, accompanied by structured education which should include clear instructions as to the place of monitoring and how results can be used to reinforce lifestyle change, adjust therapy or alert health professionals'. The results from our study strongly support these recommendations. 
